Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK4/6 Inhibitors in Medulloblastoma Patient-Derived Organoids
NCT06959979Phase 1Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1 trial in medulloblastoma (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Molecular mechanisms underlying the acquisition of resistance to CDK4/6 inhibitors at 2 years. Started Nov 2024; status: recruiting.
02
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT06959979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959979.